C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group. Chelsea and Westminster Hospital, London, UK;

Similar documents
Miss Jane Rowlands. Chelsea and Westminster Hospital, London THIRD JOINT CONFERENCE OF BHIVA AND BASHH 2014

ART Treatment. ART Treatment

Study No.: Title: Rationale: Phase: Study Period: Study Design: Centres: Indication: Treatment: Objectives: Primary Outcome/Efficacy Variable:

Abstract PS8/2. Double-blind treatment phase D/C/F/TAF. + matching D/C + F/TDF placebo D/C/F/TAF. D/C + F/TDF + matching D/C/F/TAF placebo

STRIBILD (aka. The Quad Pill)

12th European AIDS Conference / EACS ARV Therapies and Therapeutic Strategies A CME Newsletter

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh

Dr Melanie Rosenvinge

SINGLE. Efficacy and safety of dolutegravir (DTG) in treatment-naïve subjects

Initiation of antiretrovirals in HIV/HCV co-infected MSM: Are we too late?

BHIVA Best of CROI Feedback Meetings BHIVA Best of CROI Feedback Meetings 2012

The results of the ARTEN study. Vicente Soriano Hospital Carlos III, Madrid, Spain

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424138

BHIVA Audit Survey of patient assessment and monitoring. starting ART from naïve. Survey of patient assessment and monitoring

The BATAR Study Boosted Atazanavir Truvada vs. Atazanavir Raltegravir

Tenofovir Alafenamide (TAF)

Real Life Experience of Dolutegravir and Lamivudine Dual Therapy As a Switching Regimen in HIVTR Cohort

BHIVA Best of CROI Feedback Meetings. London Birmingham North West England Cardiff Gateshead Edinburgh

Dr Manisha Yapa. Chelsea and Westminster Hospital, London. 19 th Annual Conference of the British HIV Association (BHIVA)

WESTERN CAPE ART GUIDELINES PRESENTATION 2013

TDF containing ART: Efficacy and Safety. Dr Lloyd B. Mulenga Adult Infectious Diseases Centre University Teaching Hospital Lusaka, Zambia

Individual Study Table Referring to the Dossier SYNOPSIS. Final Clinical Study Report for Study AI424136

Chan HLY, Chan CK, Hui AJ, et al. Tenofovir Disoproxil Fumarate in Chronic HBV Infected Patients with Normal ALT and High HBV DNA Levels

FLAMINGO 96-WEEK PRESENTATION DATA

COMPETING INTEREST OF FINANCIAL VALUE

Antiviral Therapy 2012; 17: (doi: /IMP2305)

Clinical Management Guidelines 2012

Investigating the effect of antiretroviral switch to tenofovir alafenamide on lipid profiles in people living with HIV within the UCD ID Cohort

Pitavastatin 4 mg vs. Pravastatin 40 mg in HIV Dyslipidemia: Post- Hoc Analysis of the INTREPID Trial Based on the Independent CHD Risk Factor for Age

Purpose Methods Demographics of patients in the study Outcome. Efficacy Adverse Event. Limitation

FLAMINGO 96-WEEK PRESENTATION DATA

Differences in Calculated Glomerular Filtration Rates (GFR) in Efavirenz (EFV) or Tenofovir (TDF)-treated Adults in ESS40006

Congress report: XV Congreso Panamericano De Infectología the PROGRESS Study

First-line NNRTI to second-line PI/r

When to Rock the Boat Switching Antiretroviral Therapy for Metabolic Complications

BHIVA guidelines on the treatment of HIV-1-positive adults with antiretroviral therapy. START & other changes

Baseline renal function is an independent predictor of death and progression to severe chronic kidney disease

BHIVA antiretroviral treatment guidelines 2015

The next generation of ART regimens

Clinical considerations in switching antiretroviral therapy

COMPETING INTEREST OF FINANCIAL VALUE

Bon Usage des Antirétroviraux dans l Infection par le VIH

A Genetic Test to Screen for Abacavir Hypersensitivity Reactions

Switching antiretroviral therapy to safer strategies based on integrase inhibitors

HIV Treatment Update. Anton Pozniak Consultant Physician, Director of HIV Services Chelsea and Westminster Hospital, London

Cases from the Clinic(ians): Case-Based Panel Discussion

Dr Yvonne Gilleece Brighton and Sussex University Hospitals NHS Trust

Dr Huw Price University College London

Cabotegravir Long-Acting (LA) Injectable Nanosuspension Bill Spreen, for ViiV Healthcare & GSK Development Team. 17 th HIV-HEPPK June 2016

Integrase Strand Transfer Inhibitors on the Horizon

THE SOUTH AFRICAN ANTIRETROVIRAL TREATMENT GUIDELINES 2010

Antiretroviral Therapy: What to Start

Tenofovir plasma exposures and Creatinine Clearance changes in 1st line Regimen of African patients in Cameroon and Senegal: ANRS12115 DAYANA study

Clinical skills building - HIV drug resistance

Department of General Medicine, Juntendo University School of Medicine, Tokyo; and 2

Cabotegravir + Rilpivirine as Long-Acting Maintenance Therapy: LATTE-2 Week 32 Results

IMPROVEMENT in LIPOATROPHY ASSOCIATED with HIGHLY ACTIVE ANTIRETROVIRAL THERAPY in HIV-INFECTED CHILDREN SWITCHED from STAVUDINE to TENOFOVIR

GS-1489: STUDY DESIGN

SYNOPSIS. Clinical Study Report AI Name of Sponsor/Company: Bristol-Myers Squibb Name of Finished Product:

IAC Analyst Presentation

WHEN TO START? CROI 2015: Focus on ART

Publisher Rights Statement: 2013 The Authors. HIV Medicine published by John Wiley & Sons Ltd on behalf of British HIV Association.

Treatment experience in South Africa. Dr Ian Sanne Clinical HIV Research Unit University of the Witwatersrand

HIV Treatment: New and Veteran Drugs Classes

A study about switching from TDF to TAF

GlaxoSmithKline, London, United Kingdom; 11 ViiV Healthcare, London, United Kingdom

Hepatitis B Virus therapy. Maria Buti Hospital Universitario Valle Hebron Barcelona Spain

Treatment update. Bronagh McBrien June 2016

2.0 Synopsis. Choline fenofibrate capsules (ABT-335) M Clinical Study Report R&D/06/772. (For National Authority Use Only) Name of Study Drug:

Abacavir is associated with increased risk of cardiovascular disease in HIV-infected patients: A UK clinic case-control study

The clinical trial information provided in this public disclosure synopsis is supplied for informational purposes only.

Management of Decompensated Chronic Hepatitis B

The NEW ARV Guidelines FAQs

Integrase Inhibitors in the Treatment HIV-Infection. Andrew Zolopa, MD Stanford University

ACCEPTED. Title Page: Full Title: Elvitegravir/cobicistat/emtricitabine/tenofovir DF in HIV-Infected Patients with Mild. to Moderate Renal Impairment

Are the current doses of ARV correct. Richard Elion MD Associate Adjunct Clinical Professor of Medicine Johns Hopkins School of Medicine

Dolutegravir-Rilpivirine (Juluca)

Slide #1 Case Presentation: Kidney Disease

Professor José Arribas

Antiretroviral Treatment Strategies: Clinical Case Presentation

Doravirine vs. darunavir

38% of child bearing women with HIV in the UK would like to breastfeed PACIFY STUDY Farai Nyatsanza Imperial College Healthcare NHS Trust

Supplemental Table S2: Subgroup analysis for IL-6 with BMI in 3 groups

Application for Inclusion of Tenofovir Disoproxil Fumarate (TDF) On WHO Model List of Essential Medicines. Submitted By

Safety of switching raltegravir 400mg twice daily to raltegravir 800mg once daily in virologically suppressed patients

Perspectivesconcernantles InhibiteursNon Nucléosidiquesde la Transcriptase Inverse (INNTI)

Scottish Medicines Consortium

PDF of Trial CTRI Website URL -

RALTEGRAVIR. October Produced by the London New Drugs Group on behalf of the HIV Drugs and Treatment sub-group of the London HIV Consortium

Case 1 continued. Case 1 (cont) 12/8/16. MMAH Debate Panel Thursday, December 8, Case 1

Case # 1. Case #1 (cont d)

Trends in transmitted drug resistance to HIV-1 in the UK since 2010

Antiretroviral Drugs

Submitted By. Gilead Sciences, Inc. Foster City, California, USA. September 2006

NOTICE TO PHYSICIANS. Division of AIDS (DAIDS), National Institute of Allergy and Infectious Diseases, National Institutes of Health

Guidance for cost-sensitive HIV therapy prescribing in NHS Scotland 2017

Antiretroviral Therapy in 2016

Prima linea: dovremmo evitare i PI nella terapia di prima linea per i loro effetti non desiderati? Giuseppina Liuzzi

BHIVA Workshop: When to Start. Dr Chloe Orkin Dr Laura Waters

GSK Medicine: Study Number: Title: Rationale: Phase: Study Period: Study Design: Centers: Indication: Treatment: Objective:

Transcription:

Switching from Kivexa [KVX] (ABC/3TC) + Efavirenz [EFV] to [ATR] (EFV/FTC/TDF) Reduces Cholesterol in Hypercholesterolaemic Subjects: Primary Endpoint Results of a 24- Week Randomised Study C Orkin, 1 G Moyle, 2 M Fisher, 3 H Wang, 4 J Ewan 4 and ROCKET I Study Group 1 Barts and The London NHS Trust, London, UK; 2 Chelsea and Westminster Hospital, London, UK; 3 Brighton and Sussex University Hospitals, UK; 4 Gilead Sciences Ltd, Cambridge, UK Second Joint Conference of the British HIV Association (BHIVA) with the British Association for Sexual Health and HIV (BASHH) April 2-23, 21 Manchester, UK Abstract No. 417 17 UK Sites Newcastle Central Middlesex Royal Free North Middlesex Homerton Edinburgh Belfast Bolton Heartlands North Manchester Leicester Whittle street C & W Barts St. Georges Gloucester Brighton

Background Dyslipidaemia contributes to CV risk 1 in HIV infection Higher Triglyceride levels are independently associated with an increased risk of MI in HIV-infected people 2 Comparative studies suggest tenofovir DF-based regimens have a favourable lipid profile relative to abacavir-based regimens 3 We sought to investigate if these changes are seen in hypercholesterolaemic subjects when switched from Kivexa + Efavirenz to a single tablet regimen (STR) of 1. Grover, SA, et al., Am J Cardiol 25; 95 (5): 586-591 2. Worm, S, et al., CROI 21, Paper # 127 3. Moyle, G et al., AIDS 26; 2 (16): 243-25 RAVE Study Lipid Effects of Switching Thymidine Analogues to ABC or TDF Switch to TDF associated with improved lipid parameters Mean Change From BL at Week 48 (mg/dl (mmol/l)) 15 1 5-5 -1-15 -2-25 * P =.3* 8.1 (.21) P =.4 * P =.34 * 3.5 (.9) P =.12.4 (.1) 6.2 (.7) -4.2 (-.11) -9.7 (-.25) -29.2 (-.33) -17.5 (-.45) TC LDL HDL TG 3 2 1-1 -2-3 -4-5 * P values for between arm differences Moyle GJ, et al. AIDS. 26;2:243-25. Switch to TDF Switch to ABC

SWEET study Lipid Effects of Switching AZT to TDF Switch to TDF associated with improved lipid parameters Median Change From BL at Week 24 (mmol/l).1 - -..1 -.2 -.3 -.4 -.5 5 97 89 84 84 95 89 97 89 N c Total Cholesterol p* =.8 b LDL-c p* =.45 HDL-c p* =.82 FTC/TDF AZT/3TC c Triglyceridese p* <.1 * TVD vs CBV comparison p-value from Wilcoxon Rank Sum test s a. Treated Analysis Set, Fasted b. p <.2 c. p <.1. from Wilcoxon sign rank test orf significant change from baseline Fisher et al., JAIDS 29; 51 (5): 562-568 Objectives Primary objective: Determine whether switching from Kivexa + EFV to QD leads to a reduction in total fasting cholesterol at 12 weeks The secondary objectives: Evaluation of fasting metabolic parameters (e.g., LDL *, HDL, triglycerides, non-hdl cholesterol and cholesterol ratios) Evaluation of efficacy and safety Evaluation of changes in the 1-year risk for coronary heart disease outcomes as measured by Framingham risk score * LDL measured directly

ROCKET: Randomised Open Label Switch for Cholesterol on Kivexa Evaluation Trial* Stable Kivexa (ABC/3TC) + EFV 6 months (N=159) randomised 1:1 (TDF/FTC/EFV) KVX (ABC/3TC) + EFV Week 12 primary endpoint (TDF/FTC/EVF) (TDF/FTC/EVF) Week 24 Confirmation of Week 12 Undetectable viral load ( 5 copies/ml) 12 weeks Total cholesterol 5.2 mmol/l Adequate Baseline renal (CrCl 6mL/min and Hepatic (AST / ALT 5 x ULN) function 157 / 159 subjects enrolled received at least one dose of study drug * Presentation of data up to Week 12 Baseline Characteristics a Kivexa + Efavirenz Number of subjects 79 78 Median age in yrs (IQR) 42 (36, 48) 44 (4, 5) Race White Black Asian Other 45 (57.%) 29 (36.7%) 2 (2.5%) 3 (3.8%) 48 (61.5%) 27 (34.6%) 3 (3.9%) Gender Male 61 (77.2%) 64 (82.1%) HIV RNA b < 5 copies/ml < 4 copies/ml 76/79 (96.2%) 79/79 (1%) 71/77 (92.2%) 77/77 (1%) Median BMI (kg/m 2 ) (IQR) 25.7 (23.5, 29.3) 25.8 (23.7, 28.) Median Fasting Total Cholesterol ( IQR) 6.62 (5.97, 7.26) 6.19 (5.8, 6.78) Number of Subjects on Prior Lipid Modifying Agents a. Treated Analysis Set b. One subject in Kivexa arm did not have a baseline viral load sample 9 (11.4%) 13 (16.7%)

Subject Disposition at Week 12 a N (%) (N=79) Kivexa + Efavirenz (N=78) Subjects completing 12 weeks of study 78 (98.7%) 74 (94.9%) Treatment Discontinuation (Prior to Week 12) 1 (1.3 %) 4 (5.1%) Adverse Events b 1 (1.3%) 1 (1.3%) Pregnancy Protocol Violation 2 (2.5%) Withdrew Consent Investigator s Decision 1 (1.3%) a. Treated AnalysisSet b. Adverse Events leading to study drug discontinuation: ATR arm - anxiety / heartburn / night sweats / general body pain/ palpitations KVX arm - depression Fasting Metabolic Parameters: Week 12 - Change from Baseline MITT Analysis Set (LOCF) Excluding subjects who started / modified lipid lowering medications during the study Median Change from Baseline (mmol/l).1 -.1 -.2 -.3 -.4 -.5 -.6 -.7 -.8 -.9-1 N=76 N=74 N=76 N=74 6.6 6.19 4.5 3.92 N=75 N=74 1.4 1.44 N=76 N=74 N=75 N=73 4.8 4.4 1.84 1.66 p <.1* p <.1* p <.1* p <.1* p=.3* LDL Cholesterol Total Cholesterol HDL Cholesterol Triglycerides TC: HDL ratio Kivexa + Efavirenz * P values for between arm differences Median value at baseline (mmol/l) LDL measured directly

Coronary Heart Disease Risk by Framingham Risk Score: Week 12 Median (IQR) Change from Baseline Median (IQR) Kivexa + Efavirenz Baseline 8. (4., 13.) 8. (4., 13.) Week 12 8. (3., 13.) Change from BL to Week 12 a. (-3.,.) 8. (4., 1.). (-1.,.) a. p=.37 for ATR vs KVX +EFV comparison Viral Suppression Change by Visit ITT Analysis Set (Missing = Excluded) % Subjects with HIV RNA < 5 c/ml CD4 count Week 12 Change from Baseline % % 1 9 8 7 6 5 4 3 Kivexa + Efavirenz 92.2% 9.3% 2 1 time Baseline Week 4 Week 12 Median CD4 count (cells/m m 3) (IQR) 3 2 1-1 -2-3 459 45 p=.13* (-36, 77) time (-96, 49) Kivexa + Efavirenz Virological failure [Subjects with 2 consecutive post-baseline value 4 copies/ml]: ATR /79 (%), KVX+EFV /78 (%) Median value at baseline (cells/mm3) * p values for between arm differences

Renal Function Creatinine Clearance - Median (IQR) Cockroft Gault (ml/min) and MDRD (ml/min/1.73m 2 ) 15 Creatinine Clearance: Cockroft Gault (ml/min) - Median (IQR) 15 Estimated GFR: MDRD (ml/min/1.732 m2) - Median (IQR) 125 125 ml/min 1 75 5 ATR ml/min/1.73 m 2 1 75 5 ATR 25 KVX + EFV Normal boundary 25 KVX + EFV Normal boundary 4 Weeks 12 4 12 Weeks No subject experienced a grade 3 or 4 renal abnormality in either arm Conclusions Switching from Kivexa + Efavirenz to in subjects with hypercholesterolaemia: Significantly reduces lipid parameters Maintains virological control Switching from Kivexa + Efavirenz to is beneficial in suitable hypercholesterolaemic patients

Acknowledgements 4 The ROCKET I Study Group Greater London: J Ainsworth, A Waters (North Middlesex, London) J Anderson, L Morumba (Homerton University, London) G Brook, M Chikohora (Central Middlesex, London) P Hay, A Adebiyi, M Cockerill, M Ndoro (St. Georges, London) M Johnson, A Carroll, F Turner (Royal Free, London) G Moyle, C Fletcher, J Osorio (Chelsea & Westminster, London) C Orkin, J Hand, C Desouza (Barts & Royal London) South East England: M Fisher, N Perry, T Maher, A Bray (Brighton & Sussex University) South West England: A de Burgh Thomas, M Bunting, L Jones (Gloucester Royal) Midlands: North England: Scotland: Northern Ireland: D White, J Groves (Birmingham Heartlands) J Ross, L Brown, K Hood (Selly Oak, Birmingham) J Dhar, S Johnson (Leicester Royal Infirmary) E Morgan, R Hewart (Royal Bolton) E Ong, J Wotherspoon (Newcastle General) E Wilkins, E Stockwell, A Robertson (North Manchester General) C Leen, S Morris, L Ellis (Western General, Edinburgh) R Maw, S McKernan (Royal Victoria, Belfast) C Herath, J Ewan, M (Hui) Wang, R Ebrahimi (Gilead Sciences Limited, Cambridge) We wish to thank all the patients that participated in the study.